Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

Cancer

Volumn 122, Issue 12, 2016, Pages 1844-1852

  Matulonis, Ursula A ^a   Harter, Philipp ^b   Gourley, Charlie ^c   Friedlander, Michael ^d   Vergote, Ignace ^e   Rustin, Gordon ^f   Scott, Clare ^g   Meier, Werner ^h   Shapira Frommer, Ronnie ⁱ   Safra, Tamar ^j   Matei, Daniela ^k   Fielding, Anitra ^l   Spencer, Stuart ^l   Parry, David ^l   Grinsted, Lynda ^l   Ledermann, Jonathan A ^m  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b KLINIKEN ESSEN MITTE   (Germany)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f MOUNT VERNON HOSPITAL   (United Kingdom)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h Evangelic Hospital   (Germany)

ⁱ SHEBA MEDICAL CENTER   (Israel)

^j TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l ASTRAZENECA   (United Kingdom)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

BRCA mutation; olaparib; ovarian cancer; overall survival; poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; PLACEBO; PLATINUM COMPLEX; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; DRUG SENSITIVITY; GENE MUTATION; HAZARD RATIO; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; CLINICAL TRIAL; CONTROLLED STUDY; CYSTADENOCARCINOMA, SEROUS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; GENETICS; GERMLINE MUTATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OVARIAN NEOPLASMS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STATISTICAL ANALYSIS; SURVIVAL RATE;

BRCA1 PROTEIN; BRCA2 PROTEIN; CYSTADENOCARCINOMA, SEROUS; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; RECURRENCE; SURVIVAL RATE;

EID: 84963823064     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29995     Document Type: Article

References (16)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Hanker LC, Loibl S, Burchardi N, et al., The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012; 23: 2605-2612.
3. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474: 609-615.
4. Scott CL, Swisher EM, Kaufmann SH,. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol. 2015; 33: 1397-1406.
5. Kim G, Ison G, McKee AE, et al., FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res. 2015; 21: 4257-4261.
6. European Medicines Agency. Lynparza (olaparib). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003726/human-med-001831.jsp&mid=WC0b01ac058001d124. Accessed March 16, 2016.
7. Ledermann J, Harter P, Gourley C, et al., Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; 366: 1382-1392.
8. Ledermann J, Harter P, Gourley C, et al., Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014; 15: 852-861.
9. Robins JM, Tsiatis AA,. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory Methods. 1991; 20: 2609-2631.
10. Richards CS, Bale S, Bellissimo DB, et al., ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med. 2008; 10: 294-300.
11. AstraZeneca. Global policy: bioethics. https://www.astrazeneca.com/content/dam/az/our-company/Documents/Bioethics-Policy-v60.pdf. Accessed March 15, 2016.
12. Watkins C, Huang X, Latimer N, Tang Y, Wright EJ,. Adjusting overall survival for treatment switches: commonly used methods and practical application. Pharm Stat. 2013; 12: 348-357.
13. Jonsson L, Sandin R, Ekman M, et al., Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation. Value Health. 2014; 17: 707-713.
14. Daugherty CK, Ratain MJ, Emanuel EJ, Farrell AT, Schilsky RL,. Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol. 2008; 26: 1371-1378.
15. Robins JM,. Information recovery and bias adjustment in proportional hazards regression analysis of randomized trials using surrogate markers. Proc Biopharm Sect Am Stat Assoc. 1993: 24-33.
16. National Institute for Health and Care Excellence. Everolimus for the second-line treatment of advanced renal cell carcinoma: NICE technology appraisal guidance [TA219]. https://www.nice.org.uk/guidance/ta219. Accessed March 16, 2016.